Alector (ALEC) EBITDA Margin (2018 - 2026)
Alector's (ALEC) quarterly EBITDA Margin came in at 734.73% in Q2 2026, down 30118.0% year-over-year from N/an in Q2 2025, and up 69.16% quarter-over-quarter from 2382.31% in Q1 2026.
Analysis
Alector (ALEC) EBITDA Margin (2018 - 2026) Analysis & Trends
Alector (ALEC) has reported EBITDA Margin for 9 consecutive years, with 734.73% the latest figure, recorded in Q2 2026.
- On a quarterly basis, EBITDA Margin fell 30118.0% year-over-year to 734.73% in Q2 2026; TTM through Jun 2026 was 912.4%, a 74660.0% decrease from a year earlier, with the FY2025 full-year figure at 741.3%, down 59711.0% from the prior year.
- EBITDA Margin was 734.73% for Q2 2026 at Alector, up from 2382.31% in the prior quarter.
- Over five years, EBITDA Margin peaked at 11.87% in Q2 2022 and troughed at 2382.31% in Q1 2026.
- A 5-year average of 528.46% and a median of 318.59% in 2022 frame the typical range for EBITDA Margin.
- Across the five-year window, EBITDA Margin soared 110037 bps in 2022 and tumbled 116579 bps in 2026, its largest moves.
- Over 5 years, EBITDA Margin stood at 383.92% in 2022, then rose by 19 bps to 312.4% in 2023, then jumped by 96 bps to 13.36% in 2024, then slumped by 4647 bps to 634.38% in 2025, then dropped by 16 bps to 734.73% in 2026.
- The last three EBITDA Margin figures came in at 734.73% (Q2 2026), 2382.31% (Q1 2026), and 634.38% (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 34.95% |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -133.21% |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 37.40% |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 30.15% |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 32.54% |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -562.07% |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 17.93% |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | -23.56% |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -0.36% |
| 10 | Alector | 274.68 Mn | 101.88 Mn | - | -734.73% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -734.73% |
| Mar 31, 2026 | -2,382.31% |
| Dec 31, 2025 | -634.38% |
| Sep 30, 2025 | -1,153.62% |
| Jun 30, 2025 | -433.55% |
| Mar 31, 2025 | -1,216.52% |
| Dec 31, 2024 | -13.36% |
| Sep 30, 2024 | -315.70% |
| Jun 30, 2024 | -302.37% |
| Mar 31, 2024 | -275.01% |
| Dec 31, 2023 | -312.40% |
| Sep 30, 2023 | -555.31% |
| Jun 30, 2023 | -6.38% |
| Mar 31, 2023 | -302.83% |
| Dec 31, 2022 | -383.92% |
| Sep 30, 2022 | -321.49% |
| Jun 30, 2022 | 11.87% |
| Mar 31, 2022 | -180.29% |
| Dec 31, 2021 | -398.23% |
| Sep 30, 2021 | 69.25% |